Last reviewed · How we verify
Gabapentin Extended Release tablets
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.
Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Postherpetic neuralgia, Partial-onset seizures (adjunctive therapy), Neuropathic pain conditions.
At a glance
| Generic name | Gabapentin Extended Release tablets |
|---|---|
| Sponsor | Depomed |
| Drug class | Anticonvulsant / Analgesic |
| Target | Alpha-2-delta subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Gabapentin is an anticonvulsant and analgesic that works by modulating calcium influx through voltage-gated calcium channels, particularly those containing the alpha-2-delta-1 subunit. This reduces the release of glutamate, noradrenaline, and substance P, thereby decreasing neuronal excitability and pain signal transmission. The extended-release formulation provides sustained drug levels over 24 hours, improving convenience and potentially reducing dosing frequency compared to immediate-release formulations.
Approved indications
- Postherpetic neuralgia
- Partial-onset seizures (adjunctive therapy)
- Neuropathic pain conditions
Common side effects
- Dizziness
- Somnolence
- Peripheral edema
- Ataxia
- Headache
- Tremor
Key clinical trials
- An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS (PHASE4)
- An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS (PHASE4)
- A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS (PHASE1)
- Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women (PHASE3)
- Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty (PHASE4)
- HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder (PHASE2)
- Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome (PHASE4)
- Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabapentin Extended Release tablets CI brief — competitive landscape report
- Gabapentin Extended Release tablets updates RSS · CI watch RSS
- Depomed portfolio CI